Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337609 | 1.00 | USP2 (0.50) | USP2MEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1219006 | 0.98 | USP2 (0.48) | USP2MEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1219003 | 0.98 | USP2 (0.48) | USP2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12884734 | 0.88 | PTGS1 (0.56) | USP2MEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1216833 | 0.86 | PTGS1 (0.54) | USP2MEN1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1216829 | 0.86 | PTGS1 (0.54) | USP2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13688874 | 0.82 | DPP4 (0.42) | USP2KMT2ADPP4PTGS1KCNH2 | |
| SCHEMBL5873375 | 0.82 | DPP4 (0.42) | USP2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13688877 | 0.82 | DPP4 (0.42) | USP2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4125965 | 0.82 | DPP4 (0.42) | USP2DPP4PTGS1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4036082-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4036089-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010088050-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088050-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7741350-B1 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741350-B1 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009106980-A2 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | USP2 2051/4885MEN1 4062/4885ALDH1A1 603/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | USP2 3015/4885MEN1 1116/4885ALDH1A1 3623/4885 |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | USP2 3015/4885MEN1 1116/4885ALDH1A1 3623/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | USP2 3015/4885MEN1 1116/4885ALDH1A1 3623/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | USP2 3015/4885MEN1 1116/4885ALDH1A1 3623/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | USP2 2051/4885MEN1 4062/4885ALDH1A1 603/4885 |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | USP2 2500/4885MEN1 1806/4885ALDH1A1 1172/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | USP2 3015/4885MEN1 1116/4885ALDH1A1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.